Personalized Cancer Vaccine Enters Phase III: Melanoma Recurrence Rate Drops 71%

On January 7, 2028, BioNTech and Moderna jointly published a landmark Phase III clinical trial result in the New England Journal of Medicine. Their mRNA personalized cancer vaccine mRNA-4157/V940, combined with Keytruda treatment following surgery, reduced two-year recurrence rates by 71% in high-risk melanoma patients.

The trial enrolled 1,089 stage III and IV melanoma patients across 132 research centers worldwide. All patients underwent surgical tumor removal before being randomized to receive either the mRNA vaccine combined with Keytruda or Keytruda alone.

Results showed the vaccine group's two-year recurrence-free survival rate was 74.8% versus 43.2% in the control group. For overall survival, the vaccine group's median had not yet been reached, compared to 38 months in the control group. Safety data showed vaccine-related adverse events were primarily mild-to-moderate injection site reactions and fatigue, with serious adverse events occurring in 4.3% of patients.

The vaccine's core technology lies in personalized neoantigen design. Each patient's tumor sample undergoes whole-genome sequencing, after which an AI system identifies tumor-specific mutant proteins and designs mRNA sequences encoding up to 34 neoantigens. After injection, the patient's own cells produce these neoantigens, training the immune system to precisely recognize and attack residual cancer cells.

"This is a paradigm shift in cancer treatment," said Timothy Chan, an oncologist at Memorial Sloan Kettering Cancer Center. "We've finally moved from the one-size-fits-all chemotherapy era into truly personalized medicine."

BioNTech CEO Uğur Şahin announced plans to submit a Biologics License Application (BLA) to the FDA in the first half of 2028. Moderna simultaneously announced it will initiate similar Phase III trials in breast cancer and non-small cell lung cancer.

The vaccine's current production cost is approximately $100,000 per dose, with each patient requiring nine doses. Reducing production costs and securing insurance coverage will be critical challenges for widespread adoption.